The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer’s Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE: